IONIS PHARMACEUTICALS Business Summary

Ionis Pharmaceuticals (IONS) operates a diversified revenue model that has transitioned from a legacy of strategic R&D partnerships to a vertically integrated commercial structure. Revenue is currently driven by three primary streams: direct net product sales from independent launches such as TRYNGOLZA (olezarsen) and DAWNZERA (donidalorsen), high-margin royalties from partnered blockbusters including SPINRAZA, WAINUA, and QALSODY, and milestone payments from long-term collaborators like Biogen, AstraZeneca, and GSK. The company’s business segments are categorized by therapeutic focus in Neurology, Cardiovascular, and Rare Disease, utilizing its proprietary antisense technology (ASO) and LIgand-Conjugated Antisense (LICA) platforms. In the competitive landscape, Ionis is a primary leader in RNA-targeted therapeutics, competing directly with Alnylam Pharmaceuticals and Arrowhead Pharmaceuticals in the RNA-interference (RNAi) space and BridgeBio Pharma in the ATTR market. Ionis maintains a competitive advantage through its expansive clinical pipeline—one of the largest in the industry—and its strategic shift toward a wholly-owned commercial model intended to achieve cash flow breakeven by 2028. Founded in 1989 by Dr. Stanley T. Crooke, a pioneer in RNA-targeted medicine, Ionis is led by CEO Brett P. Monia, Ph.D., a founding scientist with over 30 years of experience in oligonucleotide drug discovery. The executive leadership team includes Chief Financial Officer Elizabeth L. Hougen, who oversees the firm’s $1.6 billion liquidity position, and Chief Development Officer Holly Kordasiewicz, Ph.D., who assumed her role in January 2026 to spearhead the company’s late-stage clinical programs. Other key executives include Chief Scientific Officer C. Frank Bennett, Ph.D., a renowned expert in antisense technology, and Kyle Jenne, Chief Global Product Strategy Officer. The board of directors is chaired by Joseph Loscalzo, M.D., Ph.D., of Harvard Medical School, and includes notable members such as B. Lynne Parshall and Michael Hayden. The company’s institutional backing is anchored by major stakeholders including BlackRock, The Vanguard Group, and Dodge & Cox, reflecting strong market confidence in Ionis’s evolution into a multi-product, commercial-stage biopharmaceutical leader.